Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model

Abstract

PD-1 (programmed-death 1), an immune-inhibitory receptor required for immune self-tolerance whose deficiency causes autoimmunity with variable severity and tissue specificity depending on other genetic factors, is expressed on activated T cells, including the transcription factor FoxP3 + Treg cells known to play critical roles in maintaining immune tolerance. However, whether PD-1 expression by the Treg cells is required for their immune regulatory function, especially in autoimmune settings, is still unclear. We found that mice with partial FoxP3 insufficiency developed early-onset lympho-proliferation and lethal autoimmune pancreatitis only when PD-1 is absent. The autoimmune phenotype was rescued by the transfer of FoxP3-sufficient T cells, regardless of whether they were derived from WT or PD-1-deficient mice, indicating that Treg cells dominantly protect against development of spontaneous autoimmunity without intrinsic expression of PD-1. The absence of PD-1 combined with partial FoxP3 insufficiency, however, led to generation of ex-FoxP3 T cells with proinflammatory properties and expansion of effector/memory T cells that contributed to the autoimmune destruction of target tissues. Altogether, the results suggest that PD-1 and FoxP3 work collaboratively in maintaining immune tolerance mostly through nonoverlapping pathways. Thus, PD-1 is modulating the activation threshold and maintaining the balance between regulatory and effector T cells, whereas FoxP3 is sufficient for dominant regulation through maintaining the integrity of the Treg function. We suggest that genetic or environmental factors that even moderately affect the expression of both PD-1 and FoxP3 can cause life-threatening autoimmune diseases by disrupting the T-cell homeostasis.immune tolerance | autoimmunity | T lymphocytes | regulatory T cell | PD-1

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer

“…These findings suggest that Treg cells may be more susceptible to epigenetic modifications by bromodomain proteins than their conventional T cell counterparts. Given that FOXP3, CTLA-4, and PD-1 are critical for Treg stability and/or function [56–58], their diminished expression or transcriptional repression may compromise tumor-Treg survival and suppressive function as we observed in lung tumor-bearing, JQ1-treated mice. Although existing reports demonstrate that certain HDAC inhibitors affect Treg biology [35, 59, 60], and ricolinostat clearly evoked deleterious effects on patient tumor-Tregs in vitro , the more profound anti-Treg effect in our in vivo lung tumor model is attributed to JQ1.…”

Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells

“…Tregs play critical roles in tumor progression through suppressing cytotoxic CD8 + T‐cell proliferation, thereby favoring cancer cell escape from immunosurveillance. The expression of co‐inhibitory molecules including CTLA‐4, PD‐1, LAG‐3, TIM‐3, and TIGIT on Tregs is critically important for their suppressive function. Major mechanisms of immunosuppression include production of suppressive cytokines, direct cytolysis, metabolic arrest, and dendritic cell (DC) suppression through cell‐to‐cell contact‐dependent and independent mechanisms .…”

LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes

“…It was reported that the absence of PD1 on Treg cells led to generation of ex-Foxp3 T cells (42). However, Foxp3 stability was maintained in the absence of LAG3 on Treg cells, suggesting distinct pathways are regulated by LAG3 in Treg cells.…”